# Quantum Biopharma Ltd.: Form 20-F for the period ended Dec 31, 2025

- Company: [Quantum Biopharma Ltd.](/companies/qntm.md) (CIK 1771885)
- Form: 20-F
- Filed: 2026-03-26
- Accepted by EDGAR: Mar 26, 2026, 20:02 ET
- Period: 2025-12-31
- Accession: 0001185185-26-001069
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/qntm20f123125.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 12 months, 2025-01-01 to 2025-12-31 | −$15.3m | ifrs-full:ProfitLossFromOperatingActivities |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | −$8.2m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | at 2025-12-31 | $1.9m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2025-12-31 | $6.5m | ifrs-full:CurrentAssets |
| Total assets | at 2025-12-31 | $11.2m | ifrs-full:Assets |
| Current liabilities | at 2025-12-31 | $6.1m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2025-12-31 | $6.1m | ifrs-full:Liabilities |
| Shareholders' equity | at 2025-12-31 | $6.9m | ifrs-full:EquityAttributableToOwnersOfParent |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1771885/000118518526001069/qntm20f123125.htm

Filed Mar 26, 2026.
Source: SEC EDGAR, the filing index for accession 0001185185-26-001069. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.